FDA Fast Tracks Halia's Breakthrough Drug for Blood Cancer Patients

Halia Therapeutics has announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to ofirnoflast for treating adult patients with lower-risk myelodysplastic syndromes (LR-MDS). The drug is a first-in-class oral NEK7 allosteric modulator designed to target the NLRP3 inflammasome, which plays a key role in chronic inflammation and bone marrow dysfunction. A recent Phase 2 trial of ofirnoflast showed promising results among 30 evaluable patients with lower-risk MDS. The study reported a 67% overall best on-study haematological improvement rate. Among transfusion-dependent participants, 56% achieved red blood cell transfusion independence for at least eight weeks, with a median duration of 28 weeks.

The drug was generally well tolerated, with no treatment-related serious adverse events recorded. Most side effects were mild, classified as grade 1 or 2. Han Myint, Chief Medical Officer of Halia Therapeutics, noted that the Phase 2 data support further development of ofirnoflast as a potential new oral treatment for the condition.

Fast Track designation allows for more frequent interactions with the FDA. It also makes the drug eligible for Accelerated Approval, Priority Review, and Rolling Review. David J. Bearss, Chief Executive Officer of Halia Therapeutics, stated that the designation reflects the significant unmet need for patients with lower-risk MDS. The company is now planning the next stage of clinical development for ofirnoflast. The Fast Track designation accelerates the regulatory process for ofirnoflast. Halia Therapeutics intends to use the benefits of this status to advance its clinical programme. The drug’s potential to address NLRP3 inflammasome-related dysfunction in lower-risk MDS remains under investigation.